Scott James S, Michaelides Iacovos N, Schade Markus
Oncology R&D, AstraZeneca 1 Francis Crick Avenue Cambridge CB2 0AA UK
Discovery Sciences, AstraZeneca 1 Francis Crick Avenue Cambridge CB2 0AA UK.
RSC Med Chem. 2024 Nov 7. doi: 10.1039/d4md00769g.
PROTACs are an emerging therapeutic approach towards targeted protein degradation. This article examines the leading examples of this modality that are in clinical development through the prism of their physicochemical properties. In particular, the optimisation of the various components of PROTACs together with the difficulties faced by medicinal chemists seeking to achieve oral bioavailability in this challenging space are outlined. Guidance, opinion and advice based on the authors' own experiences in this area are offered in the hope this may be useful to others working in this fascinating frontier of drug discovery.
PROTACs是一种新兴的靶向蛋白质降解治疗方法。本文通过其物理化学性质的视角,审视了处于临床开发阶段的该治疗方式的主要实例。特别概述了PROTACs各组分的优化,以及药物化学家在这个具有挑战性的领域中寻求实现口服生物利用度时所面临的困难。基于作者在该领域的自身经验提供了指导、观点和建议,希望这对在药物发现这一迷人前沿领域工作的其他人可能有所帮助。